论文部分内容阅读
目的:探讨建立稳定的荷人膀胱癌SCID鼠人化复合模型的方法,为在人免疫重建荷人膀胱肿瘤SCID鼠模型检测重组BCG的免疫刺激和免疫保护中打下基础。方法:经SCID鼠腹腔内注射人PBL、皮下接种RT4膀胱癌细胞,于接种后4周检测SCID鼠体内人免疫细咆水平(IgG和CD3+、CD4+、CD8+T细胞)及脾脏重量,观察皮下成瘤潜伏期及成瘤率。结果:模型组100%成瘤,病理类型为移行细胞癌;检测SCID鼠血中人IgG均一定水平存在,与对照组间差异有统计学意义(P<0.01);人CD3+、CD4+、CD8+T细胞在鼠血及脾中均有表达,而对照组均未检出(P<0.05);4周鼠脾重平均(178.9±45.2)mg。较对照组(40.6±14.8)mg差异有统计学意义(P<0.01)。结论:采用腹腔注射人PBL、皮下接种RT4膀胱癌细胞的方法可以有效地建立人化荷人膀胱癌SCID鼠模型,较好地模拟人浸润性膀胱癌体内生物学特性,是膀胱癌免疫基因治疗的较理想模型。
OBJECTIVE: To explore a method to establish a stably human SCID mouse model of human bladder cancer in charge of human bladder cancer, and lay a foundation for the immunostimulation and immune protection of recombinant human BCG in human immunodeficient mouse model of SCID. Methods: Human PBL was inoculated intraperitoneally into SCID mice and inoculated with RT4 bladder cancer cells subcutaneously. The levels of human immune cells (IgG and CD3 +, CD4 +, CD8 + T cells) and spleens of SCID mice were detected 4 weeks after inoculation. Tumor formation latency and tumor formation rate. Results: The model group had 100% tumorigenicity and the pathological type was transitional cell carcinoma. The blood levels of human IgG in SCID mice were all in a certain level (P <0.01), and the levels of human CD3 +, CD4 +, CD8 + T cells were expressed in both rat blood and spleen, but not in the control group (P <0.05). Spleen weight was (178.9 ± 45.2) mg in 4 weeks. Compared with the control group (40.6 ± 14.8) mg, the difference was statistically significant (P <0.01). Conclusion: Intraperitoneal injection of human PBL can inoculate human bladder cancer SCID mouse model effectively, which can simulate the in vivo biological characteristics of human invasive bladder cancer effectively. It is a method of immune gene therapy of bladder cancer The more ideal model.